Clinical Trials Browser

Interventional × Triptorelin Pamoate × Clear all

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT07455903 2026-03-06

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04423211 2026-03-02

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase 3 Recruiting

Prostatic Neoplasms

NCT05896566 2026-02-24

PREcoopERA

Phase 2 Completed

Breast Neoplasms

NCT06513962 2026-02-24

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Phase 3 Recruiting

Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT00066690 2026-02-06

SOFT

Phase 3 Completed

3,066 enrolled 15 charts

Breast Neoplasms

NCT05498272 2026-01-23

NePtune

Phase 2 Recruiting

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

Phase 2 Recruiting

Prostatic Neoplasms

NCT05590793 2025-09-09

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Phase 3 Completed

195 enrolled 19 charts

Prostatic Neoplasms

NCT01492972 2025-09-04

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT00667069 2025-06-05

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT05982093 2025-05-22

SOLTI-2104

Phase 2 Active not recruiting

Breast Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Phase 2 Completed

19 enrolled 18 charts

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT02346253 2025-04-03

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Phase 2/3 Active not recruiting

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Phase 2 Completed

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06282588 2024-02-28

THUNDER

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT03899077 2024-02-07

SAVE

Phase 2 Unknown

Prostatic Neoplasms

NCT05851547 2024-01-05

DEFINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT04242017 2023-12-13

LOBSTER

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT05781217 2023-11-18

URONCOR 06-24

Phase 3 Recruiting

Prostatic Neoplasms

NCT05328258 2023-10-27

ProFertil

Phase 3 Recruiting

LymphoidSarcoma

Lymphoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04727671 2023-10-24

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Phase 4 Completed

Infertility, Polycystic Ovary Syndrome

NCT04727684 2023-10-24

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Phase 4 Completed

Infertility, Polycystic Ovary Syndrome

NCT04071574 2023-05-09

CS-EOSP-ICSI

Phase 1/2 Completed

Uterine Anomalies, Endometriosis, Endometritis, Infertility, Infertility, Female, Leiomyoma, Polycystic Ovary Syndrome, Pregnancy, Ectopic, Salpingitis, Primary Ovarian Insufficiency

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

Prostatic Neoplasms

NCT00412022 2023-03-24

HOBOE

Phase 3 Unknown

Breast Neoplasms

NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

Phase 2 Unknown

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

NCT05557604 2022-09-28

STUNNIN

Phase 2 Recruiting

Neoplasms, Prostatic Neoplasms

NCT02113553 2022-09-10

Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Phase 2 Terminated

Breast Neoplasms

NCT05212857 2022-03-16

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Phase 2 Unknown

Prostatic Neoplasms

NCT05112692 2021-11-09

Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles

Phase NA Unknown

Polycystic Ovary Syndrome

NCT04248621 2021-07-29

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4 Unknown

Prostatic Neoplasms

NCT00104741 2021-02-21

Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Phase 2/3 Unknown

The Neoadjuvant Therapy

NCT00090844 2021-01-28

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

Phase 2 Terminated

49 enrolled 10 charts

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT01753297 2020-12-09

PRIORITI

Phase 4 Completed

226 enrolled 19 charts

Prostatic Neoplasms

NCT04659551 2020-12-09

GIADA

Phase 2 Completed

Breast Neoplasms

NCT02168062 2020-07-23

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Phase 2 Terminated

57 enrolled 27 charts

Prostate Adenocarcinoma

NCT02742675 2020-07-07

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Phase 2 Unknown

Prostatic Neoplasms

NCT01790126 2020-03-11

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Phase 2 Completed

90 enrolled 23 charts

Prostatic Neoplasms